Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tamar Tadmor

Showing results (91-100 of 149) with videos related to

Pageof 15
Sort By:
Acta Haematologica|March 2, 2026
Effectiveness of integrative medicine in the management of lymphoma survivors: an exploratory preference-based controlled trialIlana Levy Yurkovski, Samuel Attias, Elad Schiff, et al.
Acta Haematologica|March 12, 2024
Efficacy of Preexposure Prophylaxis with Monoclonal Antibody Tixagevimab-Cilgavimab against Emerging SARS-CoV-2 Resistant Variants in Patients with Chronic Lymphocytic LeukemiaOhad Benjamini, Tamar Tadmor, Abraham Avigdor, et al.
Haematologica|February 10, 2015
Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experienceYair Herishanu, Neta Goldschmidt, Osnat Bairey, et al.
Hematological Oncology|October 30, 2016
Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: results of a large multicenter study involving 990 patientsRaffaella Marcheselli, Alessia Bari, Tamar Tadmor, et al.
European Journal of Haematology|June 28, 2018
Outcomes of second-line treatment after fludarabine cyclophosphamide and rituximab in patients with chronic lymphocytic leukemia outside clinical trialsErel Joffe, Neta Goldschmidt, Osnat Bairey, et al.
American Journal of Hematology|April 1, 2018
Treatment patterns and clinical outcomes in high-risk newly diagnosed multiple myeloma patients carrying the 17p deletion: An observational multi-center retrospective studyYael C Cohen, Avi Saranga, Moshe E Gatt, et al.
Mayo Clinic Proceedings|June 6, 2015
Absolute Monocyte Count and Lymphocyte-Monocyte Ratio Predict Outcome in Nodular Sclerosis Hodgkin Lymphoma: Evaluation Based on Data From 1450 PatientsTamar Tadmor, Alessia Bari, Luigi Marcheselli, et al.
British Journal of Haematology|November 17, 2015
Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational studyEli Muchtar, Moshe E Gatt, Ory Rouvio, et al.
British Journal of Haematology|June 27, 2025
CCR5 predicts neurotoxicity in CAR-T-cell therapyAyal Rozenberg, Shahar Shelly, Raz Winer, et al.
Haematologica|August 13, 2013
Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: results from a large multicenter study involving 1191 patients in the pre- and post-rituximab eraTamar Tadmor, Alessia Bari, Stefano Sacchi, et al.
Pageof 15

Showing results (91-100 of 149) with videos related to

Sort By:
Pageof 15
Acta Haematologica|March 2, 2026
Effectiveness of integrative medicine in the management of lymphoma survivors: an exploratory preference-based controlled trialIlana Levy Yurkovski, Samuel Attias, Elad Schiff, et al.
Acta Haematologica|March 12, 2024
Efficacy of Preexposure Prophylaxis with Monoclonal Antibody Tixagevimab-Cilgavimab against Emerging SARS-CoV-2 Resistant Variants in Patients with Chronic Lymphocytic LeukemiaOhad Benjamini, Tamar Tadmor, Abraham Avigdor, et al.
Haematologica|February 10, 2015
Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experienceYair Herishanu, Neta Goldschmidt, Osnat Bairey, et al.
Hematological Oncology|October 30, 2016
Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: results of a large multicenter study involving 990 patientsRaffaella Marcheselli, Alessia Bari, Tamar Tadmor, et al.
European Journal of Haematology|June 28, 2018
Outcomes of second-line treatment after fludarabine cyclophosphamide and rituximab in patients with chronic lymphocytic leukemia outside clinical trialsErel Joffe, Neta Goldschmidt, Osnat Bairey, et al.
American Journal of Hematology|April 1, 2018
Treatment patterns and clinical outcomes in high-risk newly diagnosed multiple myeloma patients carrying the 17p deletion: An observational multi-center retrospective studyYael C Cohen, Avi Saranga, Moshe E Gatt, et al.
Mayo Clinic Proceedings|June 6, 2015
Absolute Monocyte Count and Lymphocyte-Monocyte Ratio Predict Outcome in Nodular Sclerosis Hodgkin Lymphoma: Evaluation Based on Data From 1450 PatientsTamar Tadmor, Alessia Bari, Luigi Marcheselli, et al.
British Journal of Haematology|November 17, 2015
Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational studyEli Muchtar, Moshe E Gatt, Ory Rouvio, et al.
British Journal of Haematology|June 27, 2025
CCR5 predicts neurotoxicity in CAR-T-cell therapyAyal Rozenberg, Shahar Shelly, Raz Winer, et al.
Haematologica|August 13, 2013
Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: results from a large multicenter study involving 1191 patients in the pre- and post-rituximab eraTamar Tadmor, Alessia Bari, Stefano Sacchi, et al.
Pageof 15